Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Meda, a specialty pharma company, has announced that its new drug application for a newly formulated higher strength azelastine nasal spray has now been accepted by the FDA as complete for substantive review after initial evaluation.
Subscribe to our email newsletter
Anders Lonner, CEO of Meda, said: “This product has the potential to become the first once-a-day nasal antihistamine in the US. Beside better tolerance with the new formulation it could also mean better compliance for patients. The product would contribute significantly to Meda’s allergy franchise.”
Meda has completed six Phase III studies and a long-term safety study, involving more than 1,600 patients in total. In these clinical studies, the product demonstrated improvement in nasal symptom relief scores in patients with seasonal and perennial allergic rhinitis, and was well tolerated, said Meda.